Skip to main content
SpringerLink
Log in

Keine Überlegenheit gegenüber der Standardtherapie

Irinotecan/Bevacizumab in der Primärtherapie nicht resezierbarer Glioblastome

  • journal club
  • Published:
InFo Neurologie & Psychiatrie Aims and scope

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Chauffert B, Feuvret L, Bonnetain F et al. Randomized phase II trial of irinotecan and bevacizumab as neo-adjuvant and adjuvant to temozolomide-based chemoradiation compared to temozolomide-chemoradiation for unresectable glioblastoma. Final results of the TEMAVIR study from ANOCEF. Ann Oncol im Druck

Download references

Author information

Authors and Affiliations

  1. Klinik für Neurologie, Universitätsspital Zürich, Zürich, Schweiz

    Michael Weller (Direktor)

Authors
  1. Michael Weller
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Weller.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weller, M. Keine Überlegenheit gegenüber der Standardtherapie. InFo Neurologie 16, 21 (2014). https://doi.org/10.1007/s15005-014-0883-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15005-014-0883-6

Search

Navigation